Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvation BioNUVB -4.41%33 PS Ratio is 14.31 as of Jul. 17, 2026, which is 79% below its 10-year median of 66.92. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Nuvation Bio ranks worse than 59.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nuvation Bio's share price is $5.64.
Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.39. Hence, Nuvation Bio's PS Ratio for today is 14.31.
The historical rank and industry rank for Nuvation Bio's PS Ratio or its related term are showing as below:
NUVB'
s PS Ratio Range Over the Past 10 Years
Min: 10.96 Med: 66.92 Max: 623.33
Current: 14.31
During the past 6 years, Nuvation Bio's highest PS Ratio was 623.33. The lowest was 10.96. And the median was 66.92.
NUVB's PS Ratio is ranked worse than 59.89% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs NUVB: 14.31
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nuvation Bio PS Ratio Related Terms
Nuvation Bio PS Ratio Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvation Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nuvation Bio's PS Ratio for today is calculated as
Nuvation Bio's Share Price of today is $5.64. Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nuvation Bio (NUVB) has a PS Ratio of 14.31 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nuvation Bio and its competitors. This is 79% below median its historical median of 66.92. Over the past decade, Nuvation Bio's PS Ratio has ranged from 10.96 to 623.33. According to the industry distribution chart, Nuvation Bio ranks #557 out of 930 companies in the Biotechnology industry, placing it in the top 59.9%.
Is Nuvation Bio's PS Ratio too high?
Nuvation Bio's current PS Ratio of 14.31 is 79% below median its 10-year median of 66.92. Over the past 10 years, this metric has ranged from a low of 10.96 to a high of 623.33. The Biotechnology industry median PS Ratio is 9.30. Nuvation Bio's value of 14.31 is 53.9% above this industry median. Based on the distribution chart, Nuvation Bio ranks #557 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's PS Ratio compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #557 out of 930 companies for PS Ratio. This places Nuvation Bio in the lower half of its industry. The industry median PS Ratio is 9.30. Nuvation Bio's value of 14.31 is 53.9% above this benchmark. Historically, Nuvation Bio's own PS Ratio has ranged from 10.96 to 623.33 over the past decade. While the company's 10-year median is 66.92 vs. the industry median of 9.30, Nuvation Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current PS Ratio of 14.31 is 53.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current PS Ratio is 14.31, which is 79% below median its own 10-year median of 66.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current PS Ratio of 14.31. The current PS Ratio is 14.31, which is 79% below median its 10-year median of 66.92 and 53.9% above the Biotechnology industry median of 9.30. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current PS Ratio is 14.31 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
